Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Titan Pharmaceuticals, Inc is a biotechnology business based in the US. Titan Pharmaceuticals shares (TTNP) are listed on the NASDAQ and all prices are listed in US Dollars. Titan Pharmaceuticals employs 21 staff and has a trailing 12-month revenue of around USD$4.8 million.
Since the stock market crash in March caused by coronavirus, Titan Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$0.14, which is 41.18% down on its pre-crash value of USD$0.238 and 32.36% down on the lowest point reached during the March crash when the shares fell as low as USD$0.1853.
If you had bought USD$1,000 worth of Titan Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$967.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$585.77.
|Latest market close||USD$0.14|
|52-week range||USD$0.142 - USD$0.4449|
|50-day moving average||USD$0.1923|
|200-day moving average||USD$0.2653|
|Wall St. target price||USD$0.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.928|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-13)||-12.50%|
|1 month (2020-09-18)||-33.14%|
|3 months (2020-07-20)||-55.23%|
|6 months (2020-04-20)||-41.05%|
|1 year (2019-10-18)||-19.91%|
|2 years (2018-10-19)||-63.00%|
|3 years (2017-10-20)||-92.63%|
|5 years (2015-10-20)||-96.77%|
|Revenue TTM||USD$4.8 million|
|Gross profit TTM||USD$-4,919,000|
|Return on assets TTM||-123.22%|
|Return on equity TTM||-3431.55%|
|Market capitalisation||USD$18 million|
TTM: trailing 12 months
There are currently 6.4 million Titan Pharmaceuticals shares held short by investors – that's known as Titan Pharmaceuticals's "short interest". This figure is 5% down from 6.8 million last month.
There are a few different ways that this level of interest in shorting Titan Pharmaceuticals shares can be evaluated.
Titan Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Titan Pharmaceuticals shares currently shorted divided by the average quantity of Titan Pharmaceuticals shares traded daily (recently around 3.9 million). Titan Pharmaceuticals's SIR currently stands at 1.65. In other words for every 100,000 Titan Pharmaceuticals shares traded daily on the market, roughly 1650 shares are currently held short.
However Titan Pharmaceuticals's short interest can also be evaluated against the total number of Titan Pharmaceuticals shares, or, against the total number of tradable Titan Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Titan Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Titan Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0551% of the tradable shares (for every 100,000 tradable Titan Pharmaceuticals shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Titan Pharmaceuticals.
Find out more about how you can short Titan Pharmaceuticals stock.
We're not expecting Titan Pharmaceuticals to pay a dividend over the next 12 months.
Titan Pharmaceuticals's shares were split on a 1:6 basis on 25 January 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Titan Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Titan Pharmaceuticals shares which in turn could have impacted Titan Pharmaceuticals's share price.
Over the last 12 months, Titan Pharmaceuticals's shares have ranged in value from as little as $0.142 up to $0.4449. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Titan Pharmaceuticals's is 0.9068. This would suggest that Titan Pharmaceuticals's shares are less volatile than average (for this exchange).
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.